文献速递免疫规划传染病防控与疫情报告

多价单体型COVID-19疫苗PHH-1V在小鼠中诱导同源与交叉中和抗体应答

Multiple monovalent COVID-19 PHH-1V vaccine adaptations elicit homologous and cross-neutralizing antibody responses in mice.
PubMed 文献 · Vaccine · 2026-06-04

该研究在BALB/c小鼠中评估针对Omicron XBB.1.16、JN.1、XEC和LP.8.1受体结合域(RBD)同源二聚体的单体型PHH-1V疫苗构建体,采用两剂基础免疫及mRNA初免后的异源加强。结果显示所有适应株加强针均显著诱导变异株匹配的中和与结合应答,疫苗耐受性良好。

要点

  • 针对XBB.1.16、JN.1、XEC和LP.8.1的PHH-1V适应株加强针均显著诱导变异株匹配的中和及结合抗体应答。
  • 除LP.8.1外,其他适应株加强针在同源中和方面倾向于优于前一构建体(XBB.1.16适应株p<0.0001)。
  • 基础免疫中更新构建体较前代增加匹配变异株中和,结合IgG总体相似,疫苗耐受良好。

核心结论

  • PHH-1V原始疫苗可作为可更新平台,确保广泛、可 campaign-ready 的SARS-CoV-2变异株覆盖。

研究设计与样本

  • 在BALB/c小鼠中评估单体型、变异株适应的PHH-1V疫苗构建体,采用两剂基础免疫及mRNA初免动物的异源加强。
  • 适应株包括Omicron XBB.1.16、JN.1、XEC和LP.8.1的RBD同源二聚体(2 μg/剂),辅以角鲨烯佐剂。
  • 免疫原性于接种后第14天通过假病毒中和试验和RBD特异性IgG检测评估,全程监测耐受性。

主要发现

  • 所有适应株加强针相对基线显著诱导变异株匹配的中和与结合应答。
  • 两两比较中,除LP.8.1外所有适应株加强针在同源中和方面倾向于优于前一构建体(XBB.1.16适应株p<0.0001,其他无统计学显著性),结合IgG保持可比。
  • 基础免疫中更新构建体较前代增加匹配变异株中和,结合IgG总体相似。
  • 疫苗接种耐受良好,仅限于短暂、轻微的注射部位炎症。

临床怎么用

  • 支持PHH-1V作为可更新疫苗平台,用于应对SARS-CoV-2变异株的持续演化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As SARS-CoV-2 continues to evolve, rapidly adaptable COVID-19 vaccines remain essential. We evaluated monovalent, variant-adapted PHH-1V-based vaccine constructs in BALB/c mice after two-dose primary vaccination and as heterologous boosters in mRNA-primed animals. Adaptations comprised Omicron XBB.1.16, JN.1, XEC, and LP.8.1 receptor-binding domain (RBD) homodimers (2 μg/dose) in squalene-based adjuvant. Immunogenicity on day 14 post-vaccination was assessed by pseudovirus-based neutralization and RBD-specific IgG assays; tolerability was monitored throughout. All adapted boosters significantly elicited variant-matched neutralizing and binding responses relative to baseline. In pairwise comparisons, all adapted boosters except LP.8.1 tended to outperform the preceding construct in homologous neutralization (p < 0.0001, XBB.1.16-adapted; non-significant for others), while binding IgG remained comparable. In primary vaccination, updated constructs increased matched-variant neutralization versus predecessors; binding IgG was similar overall. Vaccination was well tolerated, limited to transient, mild injection-site inflammation. These data support PHH-1V original vaccine as an updatable platform, ensuring broad, campaign-ready SARS-CoV-2 variant coverage.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Moros A, Deulofeu M, Ribó M, et al. Multiple monovalent COVID-19 PHH-1V vaccine adaptations elicit homologous and cross-neutralizing antibody responses in mice. Vaccine. 2026. PMID: 42242009. doi:10.1016/j.vaccine.2026.128781

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。